Skip to main content
Clinical Trials/CTRI/2020/08/027364
CTRI/2020/08/027364
Completed
Phase 3

A multicentric, randomized, double blind, parallel, comparative study to demonstrate the non-inferiority of fixed-dose combination of Efonidipine 40 mg and Chlorthalidone 12.5 mg tablets to fixed-dose combination of Cilnidipine 10 mg and Chlorthalidone 12.5 mg tablets in the management of hypertension.

Zuventus Healthcare Limited0 sites240 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Zuventus Healthcare Limited
Enrollment
240
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 15, 2022
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients aged ââ?°Â¥18 years.
  • 2\. Patients diagnosed with Stage\-I hypertension (SBP/DBP: 140\-159/90\-99 mmHg) or Stage\-II hypertension (SBP/DBP: ââ?°Â¥160/100 mmHg).
  • 3\. Patients able to switch all prior antihypertensive medications safely to study medication (Investigatorââ?¬•s discretion).
  • 4\. Patients willing to sign informed consent.

Exclusion Criteria

  • 1\. Patients with known hypersensitivity to diuretics or dihydropyridine calcium channel blockers.
  • 2\. Patients with history of severe, malignant or secondary hypertension.
  • 3\. Patient with cerebrovascular disease in the previous 3 months.
  • 4\. Patients with chronic arrhythmia, sick sinus syndrome or sinus bradycardia ( \< 50 beats/min).
  • 5\. Patients with second\- or third\-degree atrioventricular block.
  • 6\. Women who are pregnant, lactating

Outcomes

Primary Outcomes

Not specified

Similar Trials